{
    "clinical_study": {
        "@rank": "154601", 
        "acronym": "PACE", 
        "arm_group": [
            {
                "arm_group_label": "Sugar Pill", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo, once per day (QD) by mouth, 60 minutes before bedtime for 6 weeks after 1-week run-in"
            }, 
            {
                "arm_group_label": "2.5 mg/day", 
                "arm_group_type": "Experimental", 
                "description": "Dronabinol, 2.5 mg QD by mouth, 60 minutes before bedtime for 6 weeks after 1-week placebo run-in"
            }, 
            {
                "arm_group_label": "10 mg/day", 
                "arm_group_type": "Experimental", 
                "description": "Dronabinol, 10 mg QD by mouth, 60 minutes before bedtime for 4 weeks after 1-week placebo run-in and 2-week dose escalation"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a proof of concept study to determine the safety and efficacy of dronabinol for the\n      treatment of obstructive sleep apnea syndrome (OSA)."
        }, 
        "brief_title": "Safety and Efficacy Study of Dronabinol to Treat Obstructive Sleep Apnea", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Sleep Apnea, Obstructive", 
        "condition_browse": {
            "mesh_term": [
                "Apnea", 
                "Sleep Apnea Syndromes", 
                "Sleep Apnea, Obstructive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult 21 to 64 years of age;\n\n          -  15\u2264AHI \u2264 50 on screening polysomnogram (PSG)\n\n          -  ESS score \u2265 7\n\n          -  Able to understand and complete informed consent and all study assessments and forms,\n             presented in an English-speaking format;\n\n          -  Women of child-bearing potential (WCBP) must have a negative urine pregnancy test.\n             In addition sexually active WCBP must agree to use adequate contraceptive methods\n             (oral, injectable or implantable hormonal contraceptive; tubal ligation;\n             intra-uterine devices; barrier contraceptive with spermicide; or vasectomized\n             partner).\n\n        Exclusion Criteria:\n\n          -  Arterial oxygen saturation < 75% for > 5% of sleep period time on screening PSG;\n\n          -  Occupation or life situation that may impart risk by study participation (e.g.\n             commercial driver, pilot, police officer, fireman);\n\n          -  Motor vehicle accident or \"near-miss\" related to sleepiness (self-report) within 2\n             years of the first dose of study drug (Day 8);\n\n          -  Body mass index > 45 kg/m2\n\n          -  Severe obstructive sleep apnea syndrome (OSAS) that, based on the clinical judgment\n             of the Investigator, precludes delaying positive airway pressure treatment;\n\n          -  History of shift work or rotating shifts within the month prior to the first dose of\n             study drug (Day 8);\n\n          -  Prior upper airway surgery for snoring or OSAS as an adult (\u2265 18 years of age);\n\n          -  Prior non-invasive treatment for OSAS within 6 months prior to the first dose of\n             study drug (Day 8);\n\n          -  Major surgery within 6 months prior to the first dose of study drug (Day 8);\n\n          -  Bariatric surgery within 2 years prior to the first dose of study drug (Day 8). If\n             post-bariatric surgery, weight must be stable \u00b15% (self-report) for at least 6 months\n             prior to first dose of study drug (Day 8).\n\n          -  Any form of medically managed weight loss program within 6 months prior to the first\n             dose of study drug (Day 8);\n\n          -  Significant defect in nasal patency due to anatomical abnormalities or uncontrolled\n             or recurrent episodes of rhinitis;\n\n          -  Any clinically significant unstable or progressive medical condition;\n\n          -  Any primary sleep disorder other than OSAS as determined by history, physical\n             examination, or Visit 2 PSG (after 7-day screening run-in period);\n\n          -  Clinically significant or uncontrolled: chronic obstructive pulmonary disease (COPD),\n             cardiovascular disease, gastrointestinal, respiratory, pancreatic, hepatic, renal,\n             hematologic, endocrine [including insulin-dependent diabetes mellitus (IDDM)],\n             neurological, urogenital, connective tissue, dermatological, thyroid, or other\n             medical disorder;\n\n          -  Any clinically significant psychiatric disorder;\n\n          -  History of seizure disorder;\n\n          -  Treatment with any prescription antidepressant medication within 1 month prior to the\n             first dose of study drug (Day 8);\n\n          -  Treatment with sedatives, hypnotics or other psychoactive drugs within 30 days prior\n             to the first dose of study drug (Day 8);\n\n          -  Any complete blood count (CBC) or liver function test (LFT) laboratory value outside\n             the normal range which, in the clinical judgment of the Investigator renders a\n             subject inappropriate for randomization to treatment;\n\n          -  Pregnancy [as demonstrated by positive urine human chorionic gonadotropin (hCG) test]\n             or lactation;\n\n          -  Allergic to cannabinoids or sesame oil;\n\n          -  History of substance abuse (including alcohol abuse or dependence) or laboratory\n             evidence of drug abuse on the Visit 1 drug-screening panel;\n\n          -  Use of dietary supplements which in the judgment of the Investigator may impact sleep\n             or breathing behaviors;\n\n          -  Average daily caffeine consumption > 500 mg/day (~5 cups of coffee);\n\n          -  Average weekly alcohol consumption > 10 units;\n\n          -  Unwillingness to abstain from caffeine and alcohol on all days when overnight or\n             daytime testing will be performed;\n\n          -  Participation in any other investigational protocol within the 30 days prior to the\n             first dose of study drug (Day 8);\n\n          -  Any condition which, in the opinion of the Investigator, places the patient at\n             unacceptable risk if he or she were to participate in the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01755091", 
            "org_study_id": "UM1HL112856 2011-06400"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "2.5 mg/day", 
                    "10 mg/day"
                ], 
                "intervention_name": "Dronabinol", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sugar Pill", 
                "intervention_name": "Placebo (for Dronabinol)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Tetrahydrocannabinol"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 18, 2014", 
        "location": [
            {
                "contact": {
                    "email": "julielaw@uic.edu", 
                    "last_name": "Julie Law, BS", 
                    "phone": "312-996-5176"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60612"
                    }, 
                    "name": "University of Illinois at Chicago"
                }, 
                "investigator": [
                    {
                        "last_name": "Bharati Prasad, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Hui Xie, PhD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "r-ortiz@northwestern.edu", 
                    "last_name": "Rosemary Ortiz", 
                    "phone": "312-908-1024"
                }, 
                "contact_backup": {
                    "email": "natalie.pace@northwestern.edu", 
                    "last_name": "Natalie Pace", 
                    "phone": "312-908-0029"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Northwestern University"
                }, 
                "investigator": [
                    {
                        "last_name": "Phyllis Zee, MD, PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Kathy Reid, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Hrayr Attarian, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Roneil Malkani, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Cannabimimetic Treatment of Obstructive Sleep Apnea: A Proof of Concept Trial", 
        "overall_contact": {
            "email": "julielaw@uic.edu", 
            "last_name": "Julie Law, BS", 
            "phone": "312-996-5176"
        }, 
        "overall_contact_backup": {
            "email": "dwcarley@uic.edu", 
            "last_name": "David W Carley, PhD", 
            "phone": "312-996-3827"
        }, 
        "overall_official": {
            "affiliation": "University of Illinois at Chicago", 
            "last_name": "David W Carley, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Change in AHI derived as: AHI (end of treatment) minus AHI (pre-treatment)", 
                "measure": "Change in apnea/hypopnea index (AHI)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "Change in ESS derived as: ESS (end of treatment) minus ESS (pre-treatment)", 
                "measure": "Change in Epworth Sleepiness Scale (ESS)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "Change in MWT derived as: MWT (end of treatment) minus MWT (pre-treatment)", 
                "measure": "Change in sleep latency: Maintenance of Wakefulness Test (MWT)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01755091"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Illinois at Chicago", 
            "investigator_full_name": "David W. Carley", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Tolerability by Treatment Satisfaction Questionnaire for Medications (TSQM)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "AEs will be evaluated and tracked throughout subject participation (up to 8 weeks)", 
                "measure": "Adverse Events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 8 weeks"
            }, 
            {
                "description": "Change in DT (total minutes with arterial oxygen saturation below 85% during 8-hour polysomnography) derived as: DT (end of treatment) minus DT (pre-treatment)", 
                "measure": "Change in Desaturation Time (DT)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }
        ], 
        "source": "University of Illinois at Chicago", 
        "sponsors": {
            "collaborator": {
                "agency": "Northwestern University", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University of Illinois at Chicago", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}